## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.6% below STRENGTH zone (4.0-10.0%); PEG 1.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.57)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Solventum Corp Reflects on Year of Growth and Transformation**
- Source: TradingView — Track All Markets | 20251216T140834 | Bullish | Relevance: 100%
- Solventum Corp has highlighted its significant progress during its first year as a standalone public company. The company launched a long-range plan, sold a segment to optimize its portfolio, achieved six consecutive quarters of positive volume growth, initiated a $1 billion share repurchase program, and announced an acquisition to expand its offerings. This information is based on an SEC filing from December 16, 2025.

**2. Is Solventum Stock Outperforming the Nasdaq?**
- Source: inkl | 20251216T100834 | Bullish | Relevance: 100%
- Solventum Corporation (SOLV), a large-cap healthcare company, has shown strong performance, outpacing the Nasdaq Composite (NASX) over the past three months, 52 weeks, and year-to-date. The company's recent acquisition of Acera Surgical is expected to further strengthen its advanced wound care portfolio. Analysts maintain a "Moderate Buy" rating for SOLV, with a mean price target suggesting a 5.1% upside.

**3. Is Solventum Stock Outperforming the Nasdaq?**
- Source: Markets Financial Content | 20251216T053000 | Bullish | Relevance: 100%
- Solventum Corporation (SOLV) is a large-cap healthcare company focused on medical and health technology solutions. It has outperformed the Nasdaq Composite ($NASX) over the past three months, 52 weeks, and on a YTD basis, showing a bullish trend. Analysts remain moderately optimistic about SOLV's prospects, with a "Moderate Buy" rating and a price target suggesting a 5.1% premium.

**4. Trading the Move, Not the Narrative: (SOLV) Edition**
- Source: Stock Traders Daily | 20251214T221800 | Somewhat-Bearish | Relevance: 100%
- This article provides an AI-generated analysis for Solventum Corporation (NASDAQ: SOLV), highlighting weak near-term sentiment and elevated downside risk. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels based on different risk profiles. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Forward P/E 12.7x stretched relative to 5% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 12.7 |
| Current P/E | 13.4 |
| YoY Growth | 5.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 6.6pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-0.74), momentum weakening. RSI neutral at 51. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.59% (CS: 21) | Weak |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | -0.74 | Bearish |
| vs SMA20 | 0.973x | Below |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.097x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.57
- **Stop Loss:** $76.57 (5.0% risk)
- **Target:** $84.57 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 250
- **Position Value:** $20,142.50
- **Portfolio %:** 20.14%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*